More and more people are talking about Royalty Pharma over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $37.03? Only time will tell. The information below will give you a basic idea of what this investment may entail:
-
Royalty Pharma has moved 29.9% over the last year, and the S&P 500 logged a change of 17.5%
-
RPRX has an average analyst rating of buy and is -12.14% away from its mean target price of $42.15 per share
-
Its trailing earnings per share (EPS) is $2.45
-
Royalty Pharma has a trailing 12 month Price to Earnings (P/E) ratio of 15.1 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $4.39 and its forward P/E ratio is 8.4
-
The company has a Price to Book (P/B) ratio of 2.36 in contrast to the S&P 500's average ratio of 4.74
-
Royalty Pharma is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
-
RPRX has reported YOY quarterly earnings growth of 5055.8% and gross profit margins of 1.0%
-
The company has a free cash flow of $-1360302080, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
